The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants
- PMID: 15714749
- DOI: 10.1016/0049-3848(95)00081-2
The treatment of severe or recurrent deep venous thrombosis. Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants
Abstract
Deep venous thromboses can be divided into two groups according to their pathogenesis, anatomical features and differing responses to therapy. The first and most frequent consists of so-called simple venous thrombosis while the second group, which is less common, comprises severe or recurrent venous thrombosis characterised by a multifactorial pathogenesis, a mixed thrombus rich in platelets and by an incomplete response to both prophylactic and therapeutic treatment with anticoagulants (heparin or vitamin K antagonist). In a randomized, prospective blind study in patients with severe or recurrent venous thrombosis, which included 6 groups each of 100 patients, co-administration of anticoagulants with various types of antiplatelet agent, either with rheological effects (piracetam, buflomedil, pentoxifylline) or without them (dipyridamole), has shown a beneficial potentiating antithrombotic effect with those drugs possessing rheological effects and the absence of this effect with dipyridamole.
Similar articles
-
Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.Prescrire Int. 2013 May;22(138):129-33. Prescrire Int. 2013. PMID: 23819181 Review.
-
HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis.J Thromb Haemost. 2009 Apr;7(4):514-20. doi: 10.1111/j.1538-7836.2008.03235.x. Epub 2008 Nov 24. J Thromb Haemost. 2009. PMID: 19036068
-
[Patient with antithrombotic medication. Which do bleedings or preoperative?].Laryngorhinootologie. 2006 Jan;85(1):50-60; quiz 61-5. doi: 10.1055/s-2005-870375. Laryngorhinootologie. 2006. PMID: 16444657 Review. German.
-
Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.Int Angiol. 1998 Sep;17(3):135-45. Int Angiol. 1998. PMID: 9821025 Clinical Trial.
-
Antithrombotic drugs: part I.Drugs. 1976;12(1):41-68. doi: 10.2165/00003495-197612010-00002. Drugs. 1976. PMID: 789043 Review.
Cited by
-
Nutritional and anti-inflammatory interventions in chronic heart failure.Am J Cardiol. 2008 Jun 2;101(11A):89E-103E. doi: 10.1016/j.amjcard.2008.03.007. Am J Cardiol. 2008. PMID: 18514634 Free PMC article. Review.
-
Antiplatelet agents for the treatment of deep venous thrombosis.Cochrane Database Syst Rev. 2022 Jul 25;7(7):CD012369. doi: 10.1002/14651858.CD012369.pub2. Cochrane Database Syst Rev. 2022. PMID: 35876829 Free PMC article.
-
Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism.Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD003746. doi: 10.1002/14651858.CD003746.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437461 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical